Galanin is a 29 amino acid peptide originally isolated from porcine intestine, which has been found to have a wide range of biological activities1. It is involved in various physiological processes, including the modulation of hormone secretion, smooth muscle contraction, and blood glucose regulation25. The peptide has been identified in several species, including humans, rats, and pigs, and has been shown to have similar biological activities across these species4. The discovery and characterization of galanin have led to a significant interest in its potential applications in various fields, including endocrinology, gastroenterology, and cardiology.
In the field of endocrinology, galanin has been shown to have significant effects on hormone secretion. It inhibits basal and stimulated insulin secretion, as well as the secretion of somatostatin and pancreatic polypeptide2. The peptide also influences glucagon secretion, although the results in the literature are inconsistent2. Furthermore, galanin has been identified as a hypothalamic factor that can stimulate the release of growth hormone, suggesting a neuromodulatory role at the level of the median eminence8.
Galanin's role in gastroenterology is highlighted by its ability to modulate intestinal functions. It inhibits the neural release of VIP and can directly affect circular muscle motility in the intestine3. These actions suggest that galanin may be involved in the regulation of intestinal motility and could have therapeutic potential in disorders characterized by dysmotility.
In cardiology, galanin has been found to inhibit cardiac vagal action and lower blood pressure in animal models4. This indicates that galanin or its analogs could be explored as potential treatments for conditions such as hypertension or heart rate disorders.
Galanin's inhibitory effect on insulin secretion has made it a subject of interest in diabetes research. Studies have shown that both the full-length peptide and its fragments can modulate glucose-induced insulin secretion, with certain analogs even reversing the inhibitory effect of native galanin10. This suggests that galanin or its analogs could be used to develop new therapeutic agents for the treatment of diabetes.
Galanin exerts its effects through interaction with specific receptors, which have been identified in various tissues. The peptide has been shown to inhibit insulin secretion from pancreatic β-cells, possibly through the activation of ATP-regulated K+ channels, leading to repolarization and a reduction in intracellular free Ca2+ concentration2. This action suggests that galanin may play a role in the regulation of blood glucose levels. In the gastrointestinal tract, galanin can modulate the release of vasoactive intestinal polypeptide (VIP) and affect smooth muscle motility, indicating a role in the regulation of intestinal functions3. Additionally, galanin has been implicated in the modulation of cardiac vagal action and blood pressure regulation4.
CAS No.: 211230-67-0
CAS No.: 108102-98-3
CAS No.: 13966-05-7
CAS No.: 126247-74-3
CAS No.: 88166-21-6
CAS No.: 5291-26-9